{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:52:13Z","timestamp":1791355933169,"version":"4.3.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.therap.2016.02.016","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T14:32:36Z","timestamp":1458311556000},"page":"211-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Pharmacoepidemiology and its input to pharmacovigilance"],"prefix":"10.1016","volume":"71","author":[{"given":"Jean-Luc","family":"Faillie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2016.02.016_bib0100","series-title":"L\u2019histoire de la thalidomide","author":"Lenz","year":"2015"},{"issue":"240","key":"10.1016\/j.therap.2016.02.016_bib0105","first-page":"417","article-title":"Thalidomide\u00a0: une histoire riche en rebondissements et d\u2019enseignements","volume":"23","author":"La Revue Prescrire","year":"2003","journal-title":"Rev Prescrire"},{"issue":"108","key":"10.1016\/j.therap.2016.02.016_bib0110","first-page":"303","article-title":"Thalidomide: thirty years later","volume":"11","author":"La Revue Prescrire","year":"1991","journal-title":"Rev Prescrire"},{"key":"10.1016\/j.therap.2016.02.016_bib0115","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJM197104222841604","article-title":"Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women","volume":"284","author":"Herbst","year":"1971","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.therap.2016.02.016_bib0120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2515\/therapie\/2014012","article-title":"Histoire du di\u00e9thylstilbestrol","volume":"69","author":"Tournaire","year":"2014","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2016.02.016_bib0125","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2016.02.016_bib0130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2515\/therapie\/2014035","article-title":"Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center","volume":"69","author":"Abadie","year":"2014","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2016.02.016_bib0135","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","article-title":"Rates of spontaneous reporting of adverse drug reactions in France","volume":"288","author":"B\u00e9gaud","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2016.02.016_bib0140","series-title":"Berlin declaration on pharmacovigilance","author":"ISDB EU","year":"2015"},{"key":"10.1016\/j.therap.2016.02.016_bib0145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of under-reporting of adverse drug reactions: a systematic review","volume":"32","author":"Lopez-Gonzalez","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2016.02.016_bib0150","series-title":"Stephens\u2019 detection of new adverse drug reactions","first-page":"1","article-title":"Introduction","author":"Talbot","year":"2004"},{"key":"10.1016\/j.therap.2016.02.016_bib0155","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40264-014-0170-y","article-title":"Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies","volume":"37","author":"Trifir\u00f3","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2016.02.016_bib0160","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/clpt.2008.204","article-title":"Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study","volume":"85","author":"Fosb\u00f8l","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2016.02.016_bib0165","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-2125.2007.02942.x","article-title":"Diclofenac and acute myocardial infarction in patients with no major risk factors","volume":"64","author":"Jick","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"378","key":"10.1016\/j.therap.2016.02.016_bib0170","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(11)61662-0","article-title":"Pioglitazone and bladder cancer","volume":"29","author":"Hillaire-Buys","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.therap.2016.02.016_bib0175","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40264-013-0086-y","article-title":"Scientific evidence and controversies about pioglitazone and bladder cancer: which lessons can be drawn?","volume":"36","author":"Faillie","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2016.02.016_bib0180","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/clpt.2010.90","article-title":"Refilling and switching of antiepileptic drugs and seizure-related events","volume":"88","author":"Gagne","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2016.02.016_bib0185","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11096-014-0044-5","article-title":"Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection","volume":"37","author":"Patadia","year":"2015","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.therap.2016.02.016_bib0190","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00228-008-0497-3","article-title":"Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30\u00a0September 2004?","volume":"64","author":"Sommet","year":"2008","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716000354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716000354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T11:52:34Z","timestamp":1554292354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716000354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0040595716000354"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2016.02.016","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacoepidemiology and its input to pharmacovigilance","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2016.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2016.02.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}